Lantheus Medical Imaging, a global provider of diagnostic medical imaging, has signed a multi-year agreement with Mumbai-based JB Chemicals and Pharmaceuticals (JBCPL) for the distribution and marketing of ultrasound contrast imaging agent Definity vial for (Perflutren Lipid Microsphere) injectable suspension, in India. The launch expands company's presence in South Asia.
Lantheus Medical Imaging said that Definity is currently marketed in North America, Australia and New Zealand, parts of the Pacific Rim, and several countries in the Middle East.
Definity is indicated in India for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, as well as for patient use in contrast-enhanced diagnostic ultrasound imaging to improve characterization of focal lesions of the liver and kidney.
Cyrille Villeneuve, vice president and international general manager at Lantheus Medical Imaging, said: “The introduction of Definity in India reinforces the important role this diagnostic imaging agent can play in helping physicians across the globe make informed decisions about patient treatment and care.
“Accessing the Indian market is part of our global expansion strategy for Definity, and this agreement with JBCPL, a leading Indian supplier of pharmaceuticals and diagnostic imaging products, provides Lantheus with a great opportunity to sell product in this important geographic region. JBCPL has a strong marketing infrastructure and an extensive sales force, and we believe that they are the ideal partner to sell and distribute Definity in India.”
Pranabh Mody, president of JB Chemicals & Pharmaceuticals, said: “We are proud to partner with Lantheus Medical Imaging to launch Definity in India. Definity is a strategic fit for JBCPL and its addition to our product portfolio underscores our strength and continued commitment to the diagnostic medical imaging market.”